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Prof. Aiming Yu is a tenured faculty in the Department of Biochemistry & Molecular Medicine at University of California, Davis (UC-Davis) School of Medicine in Sacramento, CA. He is also a member of the Comprehensive Cancer Center at UC-Davis.

Aiming Yu obtained a B.S. degree from the Center China Normal University in 1993 and a Ph.D. degree from the Nankai University in 1998. He then received post-doctoral trainings at University of Washington in Seattle, WA (1998--2000) and West Virginia University in Morgantown, WV (2000--2002), and worked as a Research Fellow at NCI/NIH in Bethesda, MD (2002--2004). Dr. Yu became a faculty member at SUNY-Buffalo School of Pharmacy and Pharmaceutical Sciences since 2004. In 2013 Dr. Yu joined UC-Davis School of Medicine where he also serves as Director of the PK/PD Bioanalytical Core Facility.

Dr. Yu has long standing research interests in drug metabolism and transport, especially the molecular mechanisms behind variable drug metabolism and pharmacokinetics as well as multidrug resistance. His original contribution includes the discovery of role of polymorphic CYP2D6 in the *O*-demethylation metabolism of psychoactive methoxyindolealkylamines, which include the generation of serotonin from 5-methoxytryptamine, highlighting a potential "serotonin--melatonin cycle" in humans. His further research has significant contributions to the understanding of indolealkylamine pharmacology and toxicology.

Large efforts in Prof. Yu laboratory have been devoted to studying noncoding microRNA pharmacoepigenetics as well as Cancer Pharmacology and Therapy with an ultimate goal of developing novel noncoding RNA therapeutics. His studies have revealed a number of miRNAs such as miR-27b, -328, -519c, and -1291 in the regulation of CYP enzymes (*e.g*., CYP3A4) and ABC transporters (*e.g*., ABCG2/BCRP and ABCC1/MRP1). His research has also identified a depleted expression of miR-1291 in human pancreatic ductal adenocarcinoma and demonstrated a tumor suppressive role for miR-1291. Very recently Dr. Yu has developed a novel robust platform to achieve a consistent, high-yield and large-scale production of natural and biologically-active miRNA/siRNA agents, which are distinguished from currently-used synthetic miRNAs/siRNAs with extensive artificial modifications as well as vector-based DNA materials requiring transcription by host cells. Such bioengineered ncRNA agents (BERAs) represent a novel class of biologic ncRNAs for research and therapeutics.

Dr. Yu has published over 90 peer-reviewed research and review articles. The research in Prof. Yu lab has been supported by several NIH R01/U01/R41 grants.

In addition to his research, Prof. Aiming Yu has been actively involved in teaching courses in drug metabolism, pharmacology and toxicology, and drug development, and guiding graduate students and postdocs in research and career development. Dr. Yu vividly provides extensive services to the scientific community which includes various committees and advisory panels/boards. He is currently an Editorial Board Member of *Drug Metabolism and Disposition*, and *Acta Pharmaceutica Sinica B*. He also serves as a standing member of NIH *Xenobiotic and Nutrient Disposition and Action* (XNDA) Study Section.
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Dr. Xiaobo Zhong is currently a tenured Associate Professor in the Department of Pharmaceutical Sciences at the University of Connecticut School of Pharmacy. Dr. Zhong received his Bachelor's degree in Biology from Peking University, Beijing, China in 1984 and a Ph.D. in Molecular Biology from Wageningen University, The Netherlands in 1998. After a postdoctoral training in human genetics and genomics in the Department of Genetics at Yale University School of Medicine, Dr. Zhong has started his tenure-track faculty position in the Department of Pharmacology, Toxicology, and Therapeutics at the University of Kansas Medical Center since 2004 and currently a tenured faculty at the University of Connecticut after 2012.

Dr. Zhong's research is focused on identification of genetic and epigenetic factors contributing to interindividual variability of drug metabolism and development of novel approaches for personalized medicine and precision medicine. The major achievement Dr. Zhong's research has contributed to the field includes identification of genetic polymorphisms in the cytochrome P450 oxidoreductase gene and their influence on microsomal P450-mediated drug metabolism; determination of the role of CYP3A4 mRNA alternative 3′-polyadenylation in hepatocyte differentiation, liver development, and response to drug induction; deciphering of the developmental dynamic transcription of phase-I, phase-II drug metabolizing enzyme and transporter genes; establishment of association of P450 gene expression during liver development with dynamic epigenetic histone modifications; and defining of the short and long-term impacts on drug metabolism and therapeutic efficacy in adult life by drug treatment at neonatal and infant ages.

Dr. Zhong has published over 50 peer-reviewed research and review articles in the areas of drug metabolism with a particular focus on P450-mediated drug metabolism. The research in Dr. Zhong׳s laboratory has been supported by several NIH R01 and P01 grants. Dr. Zhong has served as a member in several scientific societies related to drug metabolism, including the American Society for Pharmacology and Experimental Therapeutics (ASPET) and International Society for Study of Xenobiotics (ISSX) and an editorial board member for Drug Metabolism and Disposition, Journal of Drug Metabolism and Toxicology, Acta Pharmaceutica Sinica B, and Frontiers in Pharmacogenetics and Pharmacogenomics. He has also served as a reviewer in several NIH study sections for developmental pharmacology and has been invited to present his works in many international and national meetings as well as universities. He has trained numerous postdoctoral fellows, Ph.D., Pharm.D., MSc, and undergraduate students as well as visiting scholars.
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